Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583375 | 0.83 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL956877 | 0.79 | GRM4 (0.49) | RAB9ASMN1; SMN2NPC1CDK2CYP3A4 | |
| SCHEMBL7478025 | 0.75 | NPC1 (0.79) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL20583097 | 0.74 | CDK2 (0.48) | RAB9ASMN1; SMN2CDK2KDM4ELMNA | |
| SCHEMBL18613599 | 0.74 | CDK2 (0.57) | RAB9ASMN1; SMN2NPC1CDK2KDM4E | |
| SCHEMBL3904545 | 0.74 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1CDK2MAPT | |
| SCHEMBL2591470 | 0.74 | GAA (0.58) | RAB9ASMN1; SMN2NPC1CDK2LMNA | |
| SCHEMBL211069 | 0.72 | EHMT2 (0.44) | RAB9ANPC1KDM4EMAPTL3MBTL1 | |
| SCHEMBL10714181 | 0.72 | SMN1; SMN2 (0.60) | RAB9ASMN1; SMN2NPC1KDM4ELMNA | |
| SCHEMBL31063816 | 0.72 | EPHX2 (0.50) | RAB9ASMN1; SMN2NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | CDK1, CDK13, CDK3 | RAB9A 2875/4885SMN1; SMN2 1523/4885NPC1 4721/4885 |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | RAB9A 2875/4885SMN1; SMN2 1523/4885NPC1 4721/4885 |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | RAB9A 2875/4885SMN1; SMN2 1523/4885NPC1 4721/4885 |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | RAB9A 2875/4885SMN1; SMN2 1523/4885NPC1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.